在转移性割敏感前列腺癌中开发成本效益评估的综合框架:从系统性审查中获得的见解
Christopher G Fawsitt1, Elaine Gallagher2, Alka Singh3
1Clifton Insight, Bristol, UK.
PharmacoEconomics
|August 18, 2025
概括
为转移性割敏感前列腺癌 (mCSPC) 治疗制定一个具有成本效益的框架至关重要. 本研究为mCSPC建立了一个最佳模型,以指导未来的经济评估和决策.
科学领域:
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
- 卫生技术评估 卫生技术评估
背景情况:
- 转移性割敏感前列腺癌 (mCSPC) 带来了重大的经济挑战,需要具有成本效益的治疗策略.
- 现有的mCSPC经济评估模型由于组件变化而表现出方法上的不一致性.
- 需要一个最佳的框架来标准化经济评估,并尽量减少mCSPC的结构变化.
研究的目的:
- 审查现有的mCSPC的经济评估.
- 为mCSPC建立一个全面的成本效益建模框架.
- 支持未来的经济评估和mCSPC的决策.
主要方法:
- 在mCSPC中对经济评估进行了系统文献审查 (SLR).
- 审查了健康技术评估 (HTA) 的批评和局限性.
- 建立了一个基于SLR和HTA发现的综合性成本效益建模框架.
- 进行了额外的SLR来识别成本,资源利用和健康状态公用事业数据.
主要成果:
- 马尔科夫模型和分区生存模型 (PSMs) 在mCSPC经济评估中很普遍.
- 为mCSPC提出了一种使用半马科夫结构的新型最佳框架.
- 拟议的半马尔科夫框架通过允许时间依赖的过渡率来提高灵活性.
- 通过SLR,确定了成本和效用数据的关键来源.
结论:
- 开发的最佳框架与创新医学倡议 (IMI) 的PIONEER小组推的方法相一致.
- 这一框架巩固了mCSPC中现有的建模先例.
- 它将通过结合医疗保健资源利用和实用数据,帮助评估mCSPC治疗的成本效益.
相关概念视频
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


